Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""phase I"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 23267
Tytuł:
A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Autorzy:
Huang H; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Zhang H; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Cao B; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (5), pp. 427-433. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Sarcoma*/drug therapy
Sarcoma*/pathology
Piperidines*
Pyridines*
Pyrimidines*
Humans ; Phosphatidylinositol 3-Kinases ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol.
Autorzy:
Ghanipour L; Uppsala University, Uppsala, Sweden.; Department of Surgical Sciences, Gastro Intestinal Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Jansson Palmer G; Department of Pelvic Cancer, GI Oncology and Colorectal Surgery Unit, Karolinska University Hospital, Stockholm, Sweden.
Nilsson PJ; Department of Pelvic Cancer, GI Oncology and Colorectal Surgery Unit, Karolinska University Hospital, Stockholm, Sweden.
Nordenvall C; Department of Pelvic Cancer, GI Oncology and Colorectal Surgery Unit, Karolinska University Hospital, Stockholm, Sweden.
Frödin JE; Department of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden.
Bexe Lindskog E; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden.
Asplund D; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden.
Swartling T; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden.
Graf W; Uppsala University, Uppsala, Sweden.; Department of Surgical Sciences, Gastro Intestinal Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Birgisson H; Uppsala University, Uppsala, Sweden.; Department of Surgical Sciences, Gastro Intestinal Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Syk I; Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Verwaal V; Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Brändstedt J; Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Cashin PH; Uppsala University, Uppsala, Sweden.; Department of Surgical Sciences, Gastro Intestinal Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 04; Vol. 19 (3), pp. e0294018. Date of Electronic Publication: 2024 Mar 04 (Print Publication: 2024).
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Peritoneal Neoplasms*/drug therapy
Humans ; Clinical Trials, Phase I as Topic ; Fluorouracil/therapeutic use ; Hyperthermic Intraperitoneal Chemotherapy ; Irinotecan ; Multicenter Studies as Topic ; Oxaliplatin/therapeutic use ; Quality of Life ; Randomized Controlled Trials as Topic ; Registries ; Retrospective Studies ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
Autorzy:
Kryza D; Hospices Civils de Lyon, Lyon, France. .; UNIV Lyon-Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRS Villeurbanne, Villeurbanne, 69100, France. .; Centre de médecine nucléaire Lumen, 15 rue Gabriel Sarrazin, cedex 08, Lyon, 69373, France. .
Vinceneux A; Department of Medical Oncology, Centre Leon Bérard, Lyon, France.
Bidaux AS; Department of Clinical Research, Centre Leon Berard, Lyon, France.
Garin G; Department of Clinical Research, Centre Leon Berard, Lyon, France.
Tatu D; Department of Clinical Research, Centre Leon Berard, Lyon, France.
Cropet C; Department of Biostatistics, Centre Leon Berard, Lyon, France.
Badel JN; Lumen Nuclear Medicine Department, Centre Léon Bérard, Lyon, France.
Perol D; Department of Clinical Research, Centre Leon Berard, Lyon, France.
Giraudet AL; Lumen Nuclear Medicine Department, Centre Léon Bérard, Lyon, France. .; Centre de médecine nucléaire Lumen, 15 rue Gabriel Sarrazin, cedex 08, Lyon, 69373, France. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 01; Vol. 24 (1), pp. 163. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/radiotherapy
Carcinoma, Renal Cell*/drug therapy
Lutetium*/adverse effects
Lutetium*/therapeutic use
Radioisotopes*/adverse effects
Radioisotopes*/therapeutic use
Kidney Neoplasms*/drug therapy
Kidney Neoplasms*/radiotherapy
Antigens, Surface*/metabolism
Glutamate Carboxypeptidase II*/antagonists & inhibitors
Radiopharmaceuticals*/adverse effects
Radiopharmaceuticals*/therapeutic use
Humans ; Male ; Dipeptides/adverse effects ; Dipeptides/therapeutic use ; Heterocyclic Compounds, 1-Ring/adverse effects ; Heterocyclic Compounds, 1-Ring/therapeutic use ; Prospective Studies ; Quality of Life ; Treatment Outcome ; Tumor Microenvironment ; Female ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ethical Criteria for Improved Human Subject Protections in Phase I Healthy Volunteer Trials.
Autorzy:
Walker RL; Professor of social medicine and of philosophy at the University of North Carolina at Chapel Hill.
MacKay D; Associate professor of public policy at the University of North Carolina at Chapel Hill.
Waltz M; Research associate in the Department of Social Medicine at the University of North Carolina at Chapel Hill.
Lyerly AD; Professor of social medicine and on the core faculty in the Center for Bioethics at the University of North Carolina at Chapel Hill.
Fisher JA; Professor of social medicine and on the core faculty in the Center for Bioethics at the University of North Carolina at Chapel Hill.
Pokaż więcej
Źródło:
Ethics & human research [Ethics Hum Res] 2022 Sep; Vol. 44 (5), pp. 2-21.
Typ publikacji:
Journal Article
MeSH Terms:
Clinical Trials, Phase I as Topic*
Ethics, Research*
Healthy Volunteers ; Humans ; Policy ; Vulnerable Populations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.
Autorzy:
Pepper NB; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. .
Eich HT; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Müther M; Department of Neurosurgery, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Oertel M; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Rehn S; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Spille DC; Department of Neurosurgery, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Stummer W; Department of Neurosurgery, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Pokaż więcej
Źródło:
Radiation oncology (London, England) [Radiat Oncol] 2024 Jan 22; Vol. 19 (1), pp. 11. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Aminolevulinic Acid*
Glioblastoma*/radiotherapy
Humans ; Adolescent ; Adult ; Prospective Studies ; Neoplasm Recurrence, Local/therapy ; Combined Modality Therapy ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.
Autorzy:
Venkatesan MM; US Army Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Barnoy S; US Army Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Frenck R; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
McNeal M; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.
Baqar S; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Jan 17; Vol. 19 (1), pp. e0290987. Date of Electronic Publication: 2024 Jan 17 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Shigella sonnei*
Shigella Vaccines*
Humans ; Antibodies, Bacterial ; Antigens ; Bacterial Proteins ; Immunoglobulin A ; Immunoglobulin G ; Leukocytes, Mononuclear ; Lipopolysaccharides ; Vaccination ; Vaccines, Attenuated ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.
Autorzy:
Jung YS; Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Jin BH; Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea.
Park MS; Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea.; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Kim CO; Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea.
Chae D; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jan; Vol. 13 (1), pp. 29-40. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Polymorphism, Genetic*
Ticlopidine*/analogs & derivatives
Humans ; Male ; Clopidogrel ; Cytochrome P-450 CYP2C19/genetics ; Cytochrome P-450 CYP2C19/metabolism ; Genotype ; Phenotype ; Proof of Concept Study ; Prospective Studies ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Autorzy:
Hohmann N; Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany.
Sprick MR; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Pohl M; Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
Ahmed A; Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany.
Burhenne J; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Kirchner M; Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
Le Cornet L; NCT Trial Center, NCT, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kratzmann M; NCT Trial Center, NCT, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hajda J; Pharmacovigilance Department, Coordination Centre for Clinical Trials (KKS), Heidelberg University Hospital, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Steindorf K; Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
Delorme S; Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Schlemmer HP; Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Riethdorf S; Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
van Schaik R; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Pantel K; Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Siveke J; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK Partner Site Essen) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Seufferlein T; Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Jäger D; Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Haefeli WE; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Trumpp A; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.
Springfeld C; Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Dec; Vol. 16 (12), pp. 2483-2493. Date of Electronic Publication: 2023 Nov 03.
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytostatic Agents*/therapeutic use
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/pathology
Humans ; Gemcitabine ; Cytochrome P-450 CYP3A ; Cytochrome P-450 CYP3A Inhibitors ; Deoxycytidine/adverse effects ; Cobicistat ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Paclitaxel/adverse effects ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Autorzy:
Morcos PN; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Moss J; BAST Inc. Limited, Leicester, UK.
Austin R; BAST Inc. Limited, Leicester, UK.
Hiemeyer F; Bayer AG, Berlin, Germany.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Beckert V; Bayer AG, Berlin, Germany.
Mongay Soler L; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Childs BH; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Garmann D; Bayer AG, Berlin, Germany.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1666-1686. Date of Electronic Publication: 2023 Jun 30.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols ; Pyrimidines ; Quinazolines ; Rituximab/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020.
Autorzy:
Wu X; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Zhang F; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Yu M; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Wang H; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Aug; Vol. 11 (8), pp. 903-909. Date of Electronic Publication: 2022 Jun 16.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Clinical Trials, Phase I as Topic*
Child ; China ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Family caregivers support their patient's decision to participate in a phase 1 clinical trial: Weighing the pros and cons, bearing the costs.
Autorzy:
Kogan N; Louise Granofsky Psychosocial Oncology Program, Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Tolley M; Independent Scholar, Ottawa, Ontario, Canada.
Cohen R; Departments of Oncology and Medicine, McGill University, and Lady Davis Research Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Pokaż więcej
Źródło:
Psycho-oncology [Psychooncology] 2022 Aug; Vol. 31 (8), pp. 1374-1380. Date of Electronic Publication: 2022 Apr 29.
Typ publikacji:
Journal Article
MeSH Terms:
Caregivers*/psychology
Clinical Trials, Phase I as Topic*
Neoplasms*/pathology
Neoplasms*/therapy
Patient Participation*
Humans ; Qualitative Research ; Risk Assessment ; Uncertainty
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Autorzy:
Spiers L; Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Gray M; NIHR Oxford Biomedical Research Centre, Oxford, UK.; Institute of Biomedical Engineering, University of Oxford, Marcella Wing, Botnar Research Centre, Old Rd, Headington, Oxford, OX3 7LD, UK.
Lyon P; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
Sivakumar S; Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
Bekkali N; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
Scott S; Nuffield Department of Anaesthetics, John Radcliffe Hospital, Oxford, OX3 7LE, UK.
Collins L; Department of Oncology, Oncology Clinical Trials Office (OCTO), University of Oxford, Oxford, UK.
Carlisle R; Institute of Biomedical Engineering, University of Oxford, Marcella Wing, Botnar Research Centre, Old Rd, Headington, Oxford, OX3 7LD, UK.
Wu F; Nuffield Department of Surgery, Churchill Hospital, Oxford, OX3 7LE, UK.
Middleton M; Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Coussios C; Institute of Biomedical Engineering, University of Oxford, Marcella Wing, Botnar Research Centre, Old Rd, Headington, Oxford, OX3 7LD, UK. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Sep 23; Vol. 23 (1), pp. 896. Date of Electronic Publication: 2023 Sep 23.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Pancreatic Neoplasms*/diagnostic imaging
Pancreatic Neoplasms*/drug therapy
Carcinoma, Pancreatic Ductal*/diagnostic imaging
Carcinoma, Pancreatic Ductal*/drug therapy
Polyketides*
Adult ; Humans ; Tomography, X-Ray Computed ; Doxorubicin/therapeutic use ; Anthracyclines ; Antibiotics, Antineoplastic/therapeutic use ; Clinical Trials, Phase I as Topic ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)-An open-label, single-arm Simon's two stage phase 1 study protocol.
Autorzy:
Fitzpatrick E; Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.; King's College London, London, United Kingdom.
Filippi C; Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.; King's College London, London, United Kingdom.
Jagadisan B; Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.; King's College London, London, United Kingdom.
Shivapatham D; Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
Anand H; Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.
Lyne M; Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
Stroud KD; Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.
Newton R; King's Health Partners Clinical Trials Office, London, United Kingdom.
DeLord M; School of Population Health and Environmental Sciences, King's College London, London, United Kingdom.
Douiri A; School of Population Health and Environmental Sciences, King's College London, London, United Kingdom.
Dhawan A; Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.; King's College London, London, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Jul 25; Vol. 18 (7), pp. e0288185. Date of Electronic Publication: 2023 Jul 25 (Print Publication: 2023).
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Liver Failure, Acute*/therapy
Liver Transplantation*
Mesenchymal Stem Cells*
Humans ; Alginates ; Clinical Trials, Phase I as Topic ; Hepatocytes ; Living Donors ; Microspheres ; Child
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness of a theory-based educational intervention on work-related musculoskeletal disorders preventive behaviors among assembly-line female workers: a study protocol for a randomized controlled trial.
Autorzy:
Hosseini ZS; Department of Health Education, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Tavafian SS; Department of Health Education, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. .
Ahmadi O; Department of Occupational Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Maghbouli R; Hasheminejad Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Pokaż więcej
Źródło:
Trials [Trials] 2023 Jun 05; Vol. 24 (1), pp. 377. Date of Electronic Publication: 2023 Jun 05.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Occupational Diseases*/diagnosis
Occupational Diseases*/prevention & control
Musculoskeletal Diseases*/diagnosis
Musculoskeletal Diseases*/prevention & control
Musculoskeletal Pain*
Female ; Humans ; Workplace ; Exercise ; Posture ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.
Autorzy:
Ishizuka T; Clinical Research and Education Promotion Division, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Komaki H; Clinical Research and Education Promotion Division, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.; Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Asahina Y; Clinical Research and Education Promotion Division, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Nakamura H; Clinical Research and Education Promotion Division, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Motohashi N; Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Takeshita E; Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Shimizu-Motohashi Y; Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Ishiyama A; Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Yonee C; Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima City, Kagoshima, Japan.
Maruyama S; Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima City, Kagoshima, Japan.
Hida E; Department of Biostatistics and Data Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Aoki Y; Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2023 Jun; Vol. 43 (2), pp. 277-286. Date of Electronic Publication: 2023 Apr 03.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Muscular Dystrophy, Duchenne*/drug therapy
Muscular Dystrophy, Duchenne*/genetics
Muscular Dystrophy, Duchenne*/metabolism
Humans ; Oligonucleotides, Antisense/adverse effects ; Morpholinos/adverse effects ; Exons ; Mutation ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials.
Autorzy:
Treasure M; Department of Medicine, University Hospitals Cleveland Medical Center, Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
Daly B; Frances Payne School of Nursing, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Cao S; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH, USA.
Fu P; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH, USA.
Hong A; Department of Medicine, University Hospitals Cleveland Medical Center, Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
Weinstein E; Department of Medicine, University Hospitals Cleveland Medical Center, Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
Surdam J; University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Meropol NJ; Department of Medicine, University Hospitals Cleveland Medical Center, Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
Dowlati A; Department of Medicine, University Hospitals Cleveland Medical Center, Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Jul; Vol. 10 (13), pp. 4312-4321. Date of Electronic Publication: 2021 May 25.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Clinical Trials, Phase I as Topic*
Neoplasms/*therapy
Palliative Care/*methods
Adult ; Aged ; Aged, 80 and over ; Caregivers ; Female ; Humans ; Male ; Middle Aged ; Palliative Care/statistics & numerical data ; Quality of Life ; Sex Factors ; Symptom Assessment/methods ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Process Development for the Detoxification of Fermentation Inhibitors from Acid Pretreated Microalgae Hydrolysate.
Autorzy:
Hong JW; Department of Food Science, Natural Science Building #118, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.
Gam DH; Department of Food Science, Natural Science Building #118, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.
Kim JH; Department of Food Science, Natural Science Building #118, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.
Jeon SJ; Department of Food Science, Natural Science Building #118, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.
Kim HS; Department of Physics and Nano-Science, Natural Science Building #415, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.; CEBT Co. Ltd., Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.
Kim JW; Department of Food Science, Natural Science Building #118, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.; CEBT Co. Ltd., Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam 336-708, Korea.; FlexPro Biotech. Co. Ltd., Business Start-Up Center #309, 70 Sunmoon-ro 221, Tangjeong-Myeon, Asan-si, Chungnam 336-708, Korea.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2021 Apr 22; Vol. 26 (9). Date of Electronic Publication: 2021 Apr 22.
Typ publikacji:
Journal Article
MeSH Terms:
Metabolic Detoxication, Phase I*
Biological Products/*pharmacology
Fermentation/*drug effects
Microalgae/*chemistry
Biological Products/chemistry ; Cellulose/chemistry ; Ethanol/metabolism ; Hydrolysis ; Lignin/chemistry ; Microalgae/metabolism ; Sugars/metabolism ; Temperature
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.
Autorzy:
Andrews KA; Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.; Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York, USA.
Owen JS; Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.
McCarthy J; The Royal Melbourne Hospital, The University of Melbourne at the Doherty Institute, Melbourne, Australia.
Wesche D; Certara Strategic Consulting, Princeton, New Jersey, USA.
Gobeau N; Medicines for Malaria Venture, Geneva, Switzerland.
Grasela TH; Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.
Möhrle JJ; Medicines for Malaria Venture, Geneva, Switzerland.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2021 Mar; Vol. 14 (2), pp. 712-719. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Clinical Trials, Phase I as Topic*
Models, Biological*
Antimalarials/*administration & dosage
Malaria/*drug therapy
Plasmodium/*drug effects
Antimalarials/pharmacokinetics ; Cohort Studies ; Computer Simulation ; Dose-Response Relationship, Drug ; Healthy Volunteers ; Humans ; Malaria/parasitology ; Plasmodium/pathogenicity ; Research Design ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
Autorzy:
Felix A; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif cedex, France.
Berlanga P; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif cedex, France.
Toulmonde M; Medical Oncology Department, Institut Bergonié, Bordeaux, France.
Landman-Parker J; Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital Armand Trousseau, Paris, France.
Dumont S; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Vassal G; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif cedex, France.
Le Deley MC; Direction de la Recherche Clinique et de l'Innovation, Centre Oscar Lambret, Lille, France.
Gaspar N; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif cedex, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Mar; Vol. 10 (5), pp. 1589-1604. Date of Electronic Publication: 2021 Jan 15.
Typ publikacji:
Journal Article; Systematic Review
MeSH Terms:
Bone Neoplasms/*therapy
Clinical Trials, Phase I as Topic/*standards
Clinical Trials, Phase II as Topic/*standards
Neoplasm Recurrence, Local/*therapy
Research Design/*standards
Sarcoma, Ewing/*therapy
Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase I as Topic/statistics & numerical data ; Clinical Trials, Phase II as Topic/statistics & numerical data ; Combined Modality Therapy/statistics & numerical data ; Databases, Factual/statistics & numerical data ; Humans ; Immunotherapy/statistics & numerical data ; Molecular Targeted Therapy/statistics & numerical data ; Multicenter Studies as Topic/statistics & numerical data ; Progression-Free Survival ; Randomized Controlled Trials as Topic/statistics & numerical data ; Response Evaluation Criteria in Solid Tumors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 23267

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies